Chronic hepatitis B
Drug research and approvals for chronic hepatitis B: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 105 studies of chronic hepatitis B are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 105
- Trials authorized in Canada: 17
- FDA orphan approvals: 0
- EU medicines: 6
- A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal…NCT07944482 · Phase 1 · Fujian Akeylink Biotechnology Co., Ltd. · starts Jul 3, 2026
- Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)NCT07855029 · Not reported · Zhiliang Gao · starts Jul 1, 2026
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)NCT07852091 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)NCT07845058 · Phase 2 · The Second Affiliated Hospital of Chongqing Medical University · starts Oct 10, 2023
- A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis BNCT07771140 · Phase 1 · Sunshine Lake Pharma Co., Ltd. · starts Dec 2, 2025
- Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCCNCT07769827 · Not applicable · Jinling Hospital, China · starts Dec 26, 2025
- ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB)NCT07741461 · Phase 1 · Xiamen Amoytop Biotech Co., Ltd. · starts Aug 6, 2026
- Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis BNCT07709520 · Phase 2 · Fujian Akeylink Biotechnology Co., Ltd. · starts Jul 10, 2026
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsNCT07654283 · Phase 2 · AusperBio Therapeutics Inc. · starts Sep 1, 2026
Approved 10
- EntecavirDNA polymerase/reverse transcriptase inhibitor
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Hepatitis b virus hbsag surface protein antigenSurface antigen (HBsAg) vaccine antigen
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- TelbivudineDNA polymerase/reverse transcriptase inhibitor
- Adefovir dipivoxilDNA polymerase/reverse transcriptase inhibitor
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Hepatitis b immune globulinSurface antigen (HBsAg) binding agent
- Interferon alfa-2bInterferon alpha/beta receptor agonist
Phase 3 11
- TenofovirHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- AdefovirDNA polymerase/reverse transcriptase inhibitor
- ClevudineProtein P inhibitor
- Hepatitis b virus vaccine inactivated
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- PradefovirDNA polymerase/reverse transcriptase inhibitor
- Besifovir
- DaunorubicinDNA topoisomerase II alpha inhibitor
- ThimerosalAntimicrobial preservative, used in vaccines
- Diammonium glycyrrhizinate
Phase 2 12 of 47
- VebicorvirCore antigen inhibitor
- Elebsiran
- TerfenadineHistamine H1 receptor antagonist
- HepalatideBile acid transporter inhibitor
- Inarigivir soproxil
- Tobevibart
- NivolumabProgrammed cell death protein 1 inhibitor
- SelgantolimodToll-like receptor 8 agonist
- LB80380DNA disrupting agent
- BersacapavirCore antigen modulator
- Fosclevudine alafenamide
- ImiquimodToll-like receptor 7 agonist
Phase 1 or earlier 12 of 28
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- AcetaminophenCyclooxygenase inhibitor
- CarbamazepineSodium channel alpha subunit blocker
- ItraconazoleCytochrome P450 51 inhibitor
- Phytonadione
- QuinidineSodium channel alpha subunit blocker
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Ethinyl estradiolEstrogen receptor alpha agonist
- LevonorgestrelProgesterone receptor agonist
- Alendronic acidFarnesyl diphosphate synthase inhibitor
- RosuvastatinHMG-CoA reductase inhibitor
- SimvastatinHMG-CoA reductase inhibitor
How its trials ended
883 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 205 whose ending is known, 47% met their primary endpoint, 8% missed it and 45% stopped early.
- Completed, result not reported29533%
- Status unknown24127%
- Ongoing14216%
- Met its primary endpoint9611%
- Stopped: other or unclear405%
- Stopped: sponsor or business decision243%
- Missed its primary endpoint162%
- Stopped: enrollment or feasibility162%
- Stopped: safety71%
- Stopped: lack of efficacy61%
| Oct 2, 2026 | A phase I, open-label, multi-center, dose escalation study to evaluate the safety, pk, and pd of AZD6750 in participants with chronic hepatitis B on standard…AZD6750 | AstraZeneca Pharmaceuticals | Pending |
| Jul 22, 2026 | A phase 2 multi-center, randomized, open-label study to assess the efficacy and safety of AHB-137 in nucleos(t)ide analogue-treated participants with chronic…AHB-137 | Ausperbio Therapeutics Inc. | Pending |
| Aug 11, 2023 | Phase II investigator-initiated study to understand the vaccinal effect of hbsag monoclonal ab VIR-3434 in chronic hepatitis B infectionVIR-3434 | University Health Network | Ongoing |
| Aug 16, 2021 | A double-blind, randomized, placebo-controlled, single and multiple dose study evaluating the safety, tolerability, and pharmacokinetics of AB-836, an hbv…AB-836 | Arbutus Biopharma | Closed |
| May 7, 2021 | An observer-blind, randomized study with an open-label part to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous…RO7191863 | Roche | Pending |
| Jan 21, 2021 | A randomized, phase 2a, multicenter, open-label, multiple-cohort study evaluating regimens containing vebicorvir in subjects with chronic hepatitis B virus…AB-729 / Vebicorvir (ABI-H0731) | Assembly Biosciences Incorporated | Closed |
| Oct 2, 2020 | Phase 2, double-blind, randomized, placebo-controlled study of heptcell (adjuvanted FP-02.2) as an immunotherapeutic vaccine in treatment naïve patients with…Heptcell (adjuvanted FP-02.2) | Altimmune, Inc. | Ongoing |
| Jul 10, 2020 | A phase 2 randomized, open-label, parallel-group, multicenter study to assess intrahepatic and peripheral changes of immunologic and virologic markers in…JNJ-73763989/ Peginterferon ALFA-2A | Johnson & Johnson | Closed |
| Mar 6, 2020 | A phase II, randomised, adaptive, open-label platform trial to evaluate efficacy and safety of multiple combination therapies in participants with chronic…RO7020531/ Entecavir/ Tenofovir disproxil fumarate/tenofovir alafenamide/… | Roche | Closed |
| Mar 29, 2019 | Catalyst 206: a phase 2, exploratory study evaluating the safety and antiviral efficacy of inarigivir soproxil in non-cirrhotic, hepatitis B e antigen-negative…Inarigivir soproxil (sb 9200) | Spring Bank Pharmaceuticals | Closed |
| Feb 20, 2018 | Tenofovir exalidexTreatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age) | ContraVir Pharmaceuticals, Inc. | Designated |
| Jun 17, 1991 | Monoclonal antibody to hepatitis B virus (human)Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection. | Protein Design Labs, Inc. | Designated |
| Sep 25, 2017 | Entecavir AccordEntecavir · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 18, 2017 | Entecavir Viatris (previously Entecavir Mylan)Entecavir · generic | Viatris Limited | EMA ↗ |
| Jan 9, 2017 | VemlidyTenofovir alafenamide | Gilead Sciences Ireland UC | EMA ↗ |
| Oct 23, 2009 | Lamivudine TevaLamivudine · generic | Teva B.V. | EMA ↗ |
| Jun 26, 2006 | BaracludeEntecavir | Bristol-Myers Squibb Pharma EEIG | EMA ↗ |
| Jul 29, 1999 | ZeffixLamivudine | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA